SCM
ASMB icon

Squadron Capital Management’s Assembly Biosciences ASMB Stock Holding History

Squadron Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.4M Buy
+160,000
New +$4.36M 1.36% 20

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Squadron Capital Management's ASMB Position: Q2 2026 in Review

Squadron Capital Management opened a new position in Assembly Biosciences (ASMB) in Q2 2026: 160,000 shares worth $4.4M. The stake represents 1.36% of the portfolio and ranks #20 among its holdings.

93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Squadron Capital Management held 160,000 shares of Assembly Biosciences worth $4.4M as of Q2 2026.
  • Assembly Biosciences was a new Squadron Capital Management position in Q2 2026.
  • Assembly Biosciences made up 1.36% of Squadron Capital Management's portfolio in Q2 2026, its #20 holding.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.